High dose calcitriol may reduce thrombosis in cancer patients

被引：69

作者：

Beer, Tomasz M.

Venner, Peter M.

Ryan, Christopher W.

Petrylak, Daniel P.

Chatta, Gurkamal

Ruether, J. Dean

Chi, Kim N.

Curd, John G.

DeLoughery, Thomas G.

机构：

[1] Oregon Hlth Sci Univ, Dept Med, Portland, OR 97239 USA

[2] Oregon Hlth Sci Univ, Div Hematol & Med Oncol, Portland, OR 97201 USA

[3] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada

[4] Columbia Presbyterian Med Ctr, New York, NY 10032 USA

[5] Univ Pittsburgh, Pavill Hellman Canc Ctr, Pittsburgh, PA USA

[6] Tom Baker Canc Clin, Calgary, AB, Canada

[7] Univ British Columbia, Canc Agcy, Vancouver Ctr, Vancouver, BC V5Z 1M9, Canada

[8] Novacea Inc, San Francisco, CA USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2006年 / 135卷 / 03期

关键词：

calcitriol; vitamin D; thrombosis; prostate cancer; thromboembolism;

D O I：

10.1111/j.1365-2141.2006.06322.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The incidence of venous and arterial thrombosis in a placebo-controlled randomised trial of DN-101 (high dose calcitriol) with docetaxel versus docetaxel was compared. Of the 13 thrombotic events observed in the 250 patients enroled in this study, two occurred in DN-101 and 11 in placebo-treated patients (P = 0.01). This difference remained significant after adjustment for baseline history of thrombosis, atrial fibrillation and use of anti-thrombotic agents. In vitro and vitamin D receptor (VDR) knockout mouse studies predict that nanomolar concentrations of calcitriol may act as an antithrombotic agent. We report the first clinical observation that supports this hypothesis in humans.

引用

页码：392 / 394

页数：3

共 12 条

[1] Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice [J].